Phase 3, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy: SEER-1

Trial Profile

Phase 3, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy: SEER-1

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Thymosin-beta-4 (Primary)
  • Indications Keratitis
  • Focus Registrational; Therapeutic Use
  • Acronyms SEER-1
  • Sponsors ReGenTree
  • Most Recent Events

    • 13 Jun 2017 According to a RegeneRx Biopharmaceuticals media release, the company expects to complete this study in 2018.
    • 17 Aug 2016 Planned End Date changed from 1 Aug 2016 to 1 May 2017.
    • 17 Aug 2016 Planned primary completion date changed from 1 Aug 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top